These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19165202)

  • 1. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker.
    Misawa A; Tanaka S; Yagyu S; Tsuchiya K; Iehara T; Sugimoto T; Hosoi H
    Br J Cancer; 2009 Jan; 100(2):399-404. PubMed ID: 19165202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma.
    Charlet J; Szemes M; Malik KT; Brown KW
    Mol Carcinog; 2014 May; 53(5):413-20. PubMed ID: 23280764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients.
    Haruta M; Kamijo T; Nakagawara A; Kaneko Y
    Cancer Lett; 2014 Jun; 348(1-2):167-76. PubMed ID: 24680815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma.
    Sugawara W; Haruta M; Sasaki F; Watanabe N; Tsunematsu Y; Kikuta A; Kaneko Y
    Pediatr Blood Cancer; 2007 Sep; 49(3):240-9. PubMed ID: 16937357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.
    Yagyu S; Gotoh T; Iehara T; Miyachi M; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tamura S; Tsuchiya K; Imamura T; Misawa-Furihata A; Sugimoto T; Sawada T; Hosoi H
    Clin Cancer Res; 2008 Nov; 14(21):7011-9. PubMed ID: 18980997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma.
    Saelee P; Wongkham S; Chariyalertsak S; Petmitr S; Chuensumran U
    Asian Pac J Cancer Prev; 2010; 11(6):1677-81. PubMed ID: 21338215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
    Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
    J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis.
    Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM
    Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
    Wang YC; Yu ZH; Liu C; Xu LZ; Yu W; Lu J; Zhu RM; Li GL; Xia XY; Wei XW; Ji HZ; Lu H; Gao Y; Gao WM; Chen LB
    World J Gastroenterol; 2008 May; 14(19):3074-80. PubMed ID: 18494062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection.
    Liu ZJ; Huang Y; Wei L; He JY; Liu QY; Yu XQ; Li ZL; Zhang J; Li B; Sun CJ; Liang WB; Sun AM; Qin Y
    Neoplasma; 2017; 64(5):795-802. PubMed ID: 28592132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.
    Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y
    Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
    Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
    Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
    Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
    Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
    Wang J; Wang B; Chen X; Bi J
    Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
    Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
    Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.